Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $37.8 million.

  • Dianthus Therapeutics' Shares Outstanding (Weighted Average) rose 1039.05% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year increase of 1039.05%. This contributed to the annual value of $33.3 million for FY2024, which is 54644.12% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Shares Outstanding (Weighted Average) of $37.8 million as of Q3 2025, which was up 1039.05% from $35.8 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $58.8 million in Q2 2022 and a low of $874234.0 during Q4 2022
  • Over the past 4 years, Dianthus Therapeutics' median Shares Outstanding (Weighted Average) value was $33.3 million (recorded in 2024), while the average stood at $24.5 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Shares Outstanding (Weighted Average) crashed by 9851.25% in 2023, and later skyrocketed by 381210.86% in 2024.
  • Dianthus Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $874234.0 in 2022, then surged by 489.48% to $5.2 million in 2023, then soared by 546.44% to $33.3 million in 2024, then grew by 13.45% to $37.8 million in 2025.
  • Its last three reported values are $37.8 million in Q3 2025, $35.8 million for Q2 2025, and $35.8 million during Q1 2025.